Saturday, October 09, 2004

Stealth-adapted viruses and complex chronic illnesses

Definition: The terms stealth and stealth-adapted refer to actively cell damaging (cytopathic) viruses that lack antigenic components required for effective immune recognition. Infection, therefore, does not provoke an anti-virus inflammatory reaction.

Underlying Principle: Only a relatively few virus components are targeted by the cellular immune system. This limitation is necessary because individual lymphocytes are genetically programmed to recognize single antigenic specificities. Effective lymphocyte: virus infected target cell interaction is based on multiple copies of a relatively few antigenic specificities, rather than a plethora of many antigens. Human cytomegalovirus (CMV) encodes for approximately 150 components. Yet the majority of anti-CMV cytotoxic T cells (CTL) recognize a single viral component and most of the remaining CTL are directed at only 2 additional viral components. CMV lacking these 3 critical components would not be effectively recognized.

Origins: The best characterized stealth-adapted virus arose not from human CMV but from CMV of African green monkeys. The political implication is that these stealth-adapted viruses entered the human population as contaminants of live polio virus vaccines. Stealth-adaptation can conceivably occur with any cytopathic virus, not only herpesviruses of human or animal origins, but also other DNA and RNA viruses.

Cytopathic Effects: Stealth-adapted viruses induce a characteristic foamy vacuolated cytopathic effect, usually accompanied by cell fusion (syncytia) when cultured on human or animal fibroblasts. Similar cellular changes can be observed in tissue biopsies of infected patients and in stealth-adapted virus inoculated animals. The cytopathic effect is remarkable in not being progressive in routine virus culture because of a healing repair process mediated by pigmented material that accumulates in infrequently re-fed cultures.

Alternative Cellular energy pigments (ACE-pigments). Complex intracellular structures can also be seen in tissue biopsies from stealth virus infected patients and animals. Mitochondria show extensive disruption further supporting the argument that these structures are providing an alternative (non-mitochondria) source of cellular energy. They can respond to light and other forms of electromagnetic radiation, can occasionally display ferromagnetic properties and can resonate at certain sound frequencies. They appear capable of converting physical energies into biological energy in much the same way that chlorophyll can convert sunlight into chemical energy. They differ from chlorophyll in being responsive to a much wider range of input energies.

Clinical Associations: Insight into the wide spectrum of diseases caused by stealth-adapted viruses has come from a survey of family illnesses of presumptive infectious origin. It is also provided by what we know regarding disease associations of conventional cell damaging viruses, especially CMV and from the scattered reports of microbes being detected in diseased tissues. : Because different regions of the brain carry out unique functions, this organ more than any other is particularly prone to showing signs of limited localized damage. Not surprisingly, therefore, many stealth-adapted virus infected patients will manifest evidence of brain damage. On a mild level these can include subtle changes in personality, intellect and mood, along with mild but discernable impairments in motor, sensory and/or autonomic nervous system capacity. More severe damage will result in clinical syndromes readily classified by psychiatrists and neurologists. Early lifetime exposure can affect brain development, while old age can unmask previously hidden brain damage. Herpes viruses, and in particular CMV, have been associated with illnesses affecting all of the body’s major organs. A stealth-adapted virus infection should be suspected especially in patients with accompanying neuropsychiatric disorders or a family history of pervasive unexplained complex illnesses. Hepesviruses have also long been suspected as contributing to several forms of human malignancies. A case can be made for a viral component in cancers developing in patients with a clinical or family history of a chronic fatiguing illness.

Transmission. Several accounts have confirmed sexual transmissions. This is, however, by no means the only route of disease transmission. Casual contact, especially within a family, but also in the workplace and at school, can be a source of infection. Stealth-adapted viruses can pass between humans and animals, including domestic pets. Early studies showed that a stealth-adapted virus was resilient to drying suggesting that the environment may be a source of infection. The finding of bacteria-derived sequences within a stealth-adapted virus, together with the isolation of atypical bacteria from the patient’s feces, is a strong indication of virus passage to bacteria.

Therapy: Clinical trials of natural products with ACE-pigment like activities need to be pursued. Their mineral content also has relevance to chelation procedures. I would appreciate hearing from any clinician interested in assisting with these IRB approved trials. Reports of family illnesses of presumptive infectious origin can provide useful insights into disease manifestations as well as offering the chance to directly compare products targeted to a similar stealth-adapted virus. Please communicate either by phone or via e-mail.

Kind regards, W. John Martin, M.D., Ph.D.
Founder, Center for Complex Infectious Diseases
and BioPhysics Institute, Rosemead CA 91770
Phone 626-616-2868 e-mail s3support@mail.com



Thursday, September 30, 2004

Family Illnesses of Presumptive Infectious Origin

Complex Multi-system Illnesses Occurring Within a Family: Presumptive Evidence for an Infectious Disease Process.

W. John Martin, M.D., Ph.D. Center for Complex Infectious Diseases Rosemead CA 91770

Author address: 3328 Stevens Avenue , Rosemead CA 91770 Telephone number: (626) 616-2868 Fax number (626) 799-1700 e-mail: www.s3support.com ). Efforts to develop clinical assays for ACE-pigments and for stealth virus infected bacteria were also stymied by Federal Regulations. These actions have delayed progress in addressing an important Public Health issue.

The Nation is facing a growing incidence of chronic illnesses with characteristic neuro-psychiatric symptoms. Among these illnesses, are nearly 20,000 cases of encephalitis diagnosed annually within United States hospitals (14). Even when subjected to detailed diagnostic procedures, no etiological cause can be identified in over 60% of patients with encephalitis (15). Autism rates are increasing nationwide and childhood learning and behavioral problems are overwhelming the educational facilities. The concept of stealth-adaptation is not particularly difficult to grasp, and the published data, including findings in animals inoculated with these viruses are compelling (16). The conclusive finding that several of these viruses were derived from African green monkey simian cytomegalovirus (SCMV) has implicated their origin from live polio vaccines (17-18). These vaccines were grown on kidney cells from SCMV contaminated monkeys and virus DNA was present in licensed polio vaccines (19-20). The argument that FDA investigators are unable to culture virus from contaminated vaccines is unconvincing especially given the argument that they cannot release any of the vaccines for independent testing because of proprietary restrictions. FDA has also argued in legal proceedings against a mother wishing to have the polio vaccine tested that her child had received prior to developing a severe and eventually fatal neurological illness. Efforts to test for stealth-adapted viruses in illnesses such as autism and learning disorders in children, psychiatric illnesses in adults, and neurodegenerative diseases in the elderly has been steadfastly avoided by Public Health officials. Arguably, members of the family described in this paper, as well as other individuals with brain damaging illnesses, etc, ought to bring legal suits to compel Public Health testing for infectious agents. Such action may help protect other members of society and will surely lead to the development of more targeted therapy, including the use of natural products with ACE-pigment-like activity.

References
• Linhardt PW, Walling AD. Prurigo nodularis. J Fam Pract. 37:495-8, 1993.
• Accioly-Filho LW, Nogueira A, Ramos-e-Silva M. Prurigo nodularis of Hyde: an update. J Eur Acad Dermatol Venereol. 14:75-82, 2000.
• Wykoff RF. Delusions of parasitosis: a review. Rev Infect Dis. 9:433-7,1987.
• Ait-Ameur A, Bern P, Firoloni MP, Menecier P. Delusional parasitosis or Ekbom's syndrome. Rev Med Interne. 21:182-6, 2000.
• Martin WJ, Zeng LC, Ahmed K, Roy M. Cytomegalovirus-related sequences in an atypical cytopathic virus repeatedly isolated from a patient with the chronic fatigue syndrome. Am. J. Path. 145: 441-452, 1994.
• Martin WJ. Stealth virus isolated from an autistic child. J. Aut. Dev. Dis. 25:223-224,1995.
• Martin WJ. Simian cytomegalovirus-related stealth virus isolated from the cerebrospinal fluid of a patient with bipolar psychosis and acute encephalopathy. Pathobiology 64:64-66, 1996.
• Martin WJ. Severe stealth virus encephalopathy following chronic fatigue syndrome-like illness: Clinical and histopathological features. Pathobiology 64:1-8, 1996.
• Martin WJ. Stealth viral encephalopathy: Report of a fatal case complicated by cerebral vasculitis. Pathobiology 64:59-63, 1996.
• Martin WJ, Anderson D: Stealth virus epidemic in the Mohave Valley . Initial report of viral isolation. Pathobiology 65:51-56, 1997.
• Martin WJ, Anderson D. Stealth Virus Epidemic in the Mohave Valley : Severe vacuolating encephalopathy in a child presenting with a behavioral disorder. Exp Mol Pathol. 66:19-30 1999.
• Martin WJ. Complex intracellular inclusions in the brain of a child with a stealth virus encephalopathy. Exp Mol Path 74: 179-209, 2003.
• Martin WJ. Stealth virus culture pigments: A potential source of cellular energy. Exp. Mol. Path. 74: 210-223, 2003.
• Khetsuriani N, Holman RC, Anderson LJ. Burden of encephalitis-associated hospitalizations in the United States, 1988-1997. Clin Infect Dis. 2002 Jul 15;35(2):175-82.
• Glaser CA, Gilliam S, Schnurr D, Forghani B, Honarmand S, Khetsuriani N, Fischer M, Cossen CK, Anderson LJ; California Encephalitis Project, 1998-2000. In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998-2000. Clin Infect Dis. 36:731-42, 2003.
• Martin WJ, Glass RT. Acute encephalopathy induced in cats with a stealth virus isolated from a patient with chronic fatigue syndrome. Pathobiology 63: 115-118, 1995.
• Martin WJ, Ahmed KN, Zeng LC, Olsen J-C, Seward JG, Seehrai JS. African green monkey origin of the atypical cytopathic 'stealth virus' isolated from a patient with chronic fatigue syndrome. Clin. Diag. Virol. 4: 93-103, 1995.
• Martin WJ. Stealth adaptation of an African green monkey simian cytomegalovirus. Exp Mol Path. 66:3-7, 1999.
• Sierra-Honigmann AM, Krause PR. Live oral poliovirus vaccines and simian cytomegalovirus. Biologicals. 30:167-74, 2002.
• Baylis SA, Shah N, Jenkins A, Berry NJ, Minor PD. Simian cytomegalovirus and contamination of oral poliovirus vaccines. Biologicals. 31:63-73, 2003.